NCT02722967View on ClinicalTrials.gov

Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions

SchizophreniaMajor Depressive DisorderBipolar I Disorder

Interventions

DRUG

Aripiprazole + IEM (Ingestible Event Marker)

Oral aripiprazole (2, 5, 10, 15, 20, or 30 mg) with an ingestible event marker in a single daily dose for duration of the trial.

Trial Locations (4)

14603

Rochester

23230

Richmond

27714

Durham

91344

Granada Hills

All Listed Sponsors

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT02722967 - Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System | Biotech Hunter | Biotech Hunter